NCT03482713 - Study of Gefapixant (MK-7264) in Adult Japanese Participants With Unexplained or Refractory Chronic Cough (MK-7264-033) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 16, 2018

Primary Completion Date

June 7, 2018

Study Completion Date

June 7, 2018

Conditions

Chronic Cough

Interventions

DRUG

Gefapixant 45 mg

Gefapixant 45 mg (film-coated tablet) to be administered orally BID

DRUG

Placebo

Placebo (film-coated tablet) matching gefapixant to be administered orally BID

Trial Locations (16)

467-8602

Nagoya City University Hospital ( Site 3328), Nagoya

064-0804

Idaimae Minamiyojo Int Clinic ( Site 3321), Sapporo

675-0101

Tsumura Cardiovascular-internal-medicine Clinic ( Site 3314), Kakogawa

312-0057

Hitachi, Ltd. Hitachinaka General Hospital ( Site 3301), Hitachi-Naka

920-0353

Saiseikai Kanazawa Hospital ( Site 3337), Kanazawa

923-8560

Komatsu Municipal Hospital ( Site 3308), Komatsu

761-8073

Kamei Internal Medicine and Respiratory Clinic ( Site 3309), Takamatsu

231-8682

Yokohama City Minato Red Cross Hospital ( Site 3306), Yokohama

515-8544

Matsusaka City Hospital ( Site 3325), Matsusaka

940-2085

Nagaoka Red Cross Hospital ( Site 3307), Nagaoka

577-0843

Kawaguchi Respiratory Clinic ( Site 3304), Higashiosaka

960-1295

Fukushima Medical University Hospital ( Site 3338), Fukushima

101-0041

Doujin Memorial Medical Foundation, Meiwa Hospital ( Site 3310), Tokyo

103-0022

Nihonbashi Medical & Allergy Clinic ( Site 3334), Tokyo

103-0027

Fukuwa Clinic ( Site 3311), Tokyo

142-8666

Showa University Hospital ( Site 3331), Tokyo

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY